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Psoriatic Arthritis: The need for early intervention.  
Verna Wright Lecture 
Neil J McHugh 
About 30% of individuals with skin psoriasis will develop an inflammatory disease of the 
peripheral or axial skeleton involving synovial and/or entheseal tissue termed psoriatic 
arthritis. In most cases psoriasis will precede psoriatic arthritis by several years. Hence skin 
psoriasis provides an opportune model to investigate genetic and environmental factors 
that interact and contribute to the development of a common form of inflammatory 
arthritis. Furthermore, the pre-existing presence of psoriasis represents a unique 
opportunity for the early detection of arthritis and the potential for more effective 
intervention. However despite the presence of psoriasis there may be delay in diagnosis of 
psoriatic arthritis that is associated with adverse long-term outcome. Undiagnosed disease 
is not uncommon as demonstrated by studies applying screening questionnaires to primary 
care and dermatology clinic populations. Other potential risk factors such as obesity and 
smoking, the presence of certain genetic and biomarker profiles, combined with accurate 
imaging modalities, offer the potential for more targeted screening. So in future it should be 
possible to detect psoriatic arthritis at a much earlier stage and prevent significant joint 
damage and associated disability before it happens. 
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Introduction 
The concept of psoriatic arthritis (PsA) owes much to the insightful studies of Verna Wright. 
In one of his earliest studies 42 cases of psoriasis with arthritis were described and 
compared with 55 unselected patients with rheumatoid arthritis and 310 patients with 
psoriasis alone (1). He concluded that most of the 42 cases comprised a distinct entity. Of 
interest he was surprised by finding nail changes in four male patients with osteoarthritis, 
although possibly he may have been witnessing the bony proliferative element of PsA we 
recognise today. Notwithstanding he was the first to document the topographical 
association between nail disease and distal interphalangeal joint disease. In a later paper he 
demonstrated many of the characteristic radiological features of PsA such as osteolysis and 
a greater incidence of sacro-iliac joint change (2).  His conclusion that psoriatic arthritis ‘was 
less severe than rheumatoid arthritis’ is somewhat more contentious, but most certainly his 
observations of the different phenotypes of psoriatic arthritis were landmark findings.  
 
We now recognise that psoriatic arthritis is not a benign condition, and with more effective 
treatments available there may never be a better opportunity for preventing its 
development from an early stage. Skin psoriasis precedes the development of PsA in the 
majority of cases and so represents an excellent opportunity for implementing screening 
strategies. Some of the evidence for the important of early detection will be reviewed, as 
will recent epidemiological findings, the development of screening questionnaires and 
identification of high risk groups where screening should be applied. The review is not 
comprehensive and concentrates on selective recent findings. 
 
Is psoriatic arthritis under-diagnosed? 
Published estimates of the incidence and prevalence of psoriatic arthritis have varied, most 
likely due to the type of study setting, differences in the method of case ascertainment, and 
developments in diagnostic or classification criteria, such as the more recent adoption of 
CASPAR criteria (3).  A systematic review reported a median incidence of 6.4/100,000 cases 
per year of psoriatic arthritis in the general population (4), yet a more recent population 
based study from Norway found 188 incidence cases over an 8 year period giving an 
incident rate of 41.3/100,000 (5). In a longitudinal retrospective population based study of 
psoriasis using a medical records linked system, there was a 10 year cumulative incidence of 
3.1% in Olmsted County Minnesota (6). In contrast, a prospective cohort study of psoriasis 
in Toronto reported a higher incidence of 1.8% (7). However both incidence and prevalence 
of PsA may be even higher. Studies using screening questionnaires applied to psoriasis 
populations in dermatology and primary care settings have revealed that many patients are 
undiagnosed. In a German study there were 10.9 % of patients from dermatology clinics 
with undiagnosed psoriatic arthritis (8) and as many as 29% in a study from Dublin (9). 
Although retrospective studies do point to the potential importance of early diagnosis, it is 
important to note that the natural history of undiagnosed PsA is unknown. 
 
Observational studies of outcome in PsA 
Long-term observational studies of PsA have provided valuable information on the natural 
history of PsA. Health-related quality of life measures are impacted upon in a similar degree 
to rheumatoid arthritis (10). An atherogenic lipid profile is associated with active psoriatic 
arthritis (11), there is an increased incidence of subclinical atherosclerosis (12, 13) and an 
increased risk of cardiovascular disease (14) Joint damage occurs in 47% of patients within 
two years of disease onset (15). 
 
Several studies of longitudinal disease cohorts suggest that delay in diagnosis is associated 
with a worse outcome. In the Toronto cohort a greater rate of joint damage was reported in 
those patients first seen after two years of diagnosis compared to those seen within two 
years (16). In our own Bath cohort, delay in diagnosis, smoking, female gender and older age 
at onset were associated with a worse physical function measured by the Health 
Assessment Questionnaire (HAQ) after 10 years (17). Similar observations were reported in 
a Dublin cohort with late consulters having greater peripheral joint erosion and worse 
physical function (18). In a prospective study from the Swedish Early Psoriatic Arthritis 
Register a shorter duration of symptoms and lower HAQ scores were independent 
predictors of reaching a state of minimal disease activity at 5 years (19). Therefore there is 
increasing evidence that early intervention may be important in reducing the burden of 
disease, although further prospective studies are needed. 
 
Detection of early disease 
i. Screening questionnaires 
There have been several questionnaires available to screen for patients with PsA in various 
settings. The performance of the questionnaire has been compared in several studies, such 
as two comparing the Psoriatic Arthritis Screening Evaluation (PASE), the Toronto Psoriatic 
Arthritis Screen (ToPAS) and the Psoriasis Epidemiology Screening Tool (PEST) (9, 20) and 
another the Psoriasis and Arthritis Screening Questionnaire (PASQ) with ToPAS and PEST 
(21). In general the screening tools help identify a substantial number of patients with 
undiagnosed PsA and patients who may benefit from rheumatology review. A further 
questionnaire (CONTEST) has been derived combining optimal questions from existing tools 
and needs further evaluation (22). Questions remain regarding the appropriate health care 
setting in which to apply the questionnaires, the frequency of their use and the 
characteristics of the target population. Also patients with PsA may have mild psoriasis that 
never comes to health-care attention until after PsA is diagnosed and so they may not be 
captured by screening. 
 
ii. imaging 
Imaging studies have revealed preclinical disease in patients with psoriasis alone. Indeed 
patients with psoriasis clinically asymptomatic for musculoskeletal disease have a higher 
prevalence of entheseal abnormalities on ultrasound than age and sex-matched controls 
(23). Power Doppler may detect vascular changes that distinguish PsA from psoriasis alone 
and offers the potential for detecting early that development of arthritis (24). Psoriasis 
patients with nail changes had higher enthesitis scores at remote sites than patients with 
normal nails, consistent with observations that patients with PsA have a greater frequency 
of nail disease than psoriasis patients alone (25). MRI scanning may reveal subclinical 
synovitis and enthesitis inpatients with psoriasis without arthritis symptoms (26). 
 
Risk factors for psoriatic arthritis in psoriasis 
i. Clinical and lifestyle 
There are relatively few studies addressing the pattern of psoriasis as a risk factor for PsA. 
One such study found that scalp and intergluteal psoriasis and nail disease put those 
individuals at risk of developing PsA (6). Nail disease is more common in patients with PsA 
compared to psoriasis and has been confirmed as a risk factor in a more recent study(27). 
Evidence for smoking as a risk factor is more conflicting with at least two studies finding 
smoking a positive risk factor (17, 28) and another reporting that smoking is protective (29). 
A population based study using The Health improvement Network (THIN) database reported 
a greater incidence rate of PsA in a psoriasis population with increasing BMI (30). At least 
one study has reported the prevalence of PsA to be associated with greater extent of 
psoriasis (31) albeit most patients with PsA have mild psoriasis and low PASI scores. 
Although the median time of onset of PsA is within 10 years of the onset of psoriasis (31), 
notably one study of European dermatology centres found the incidence rate of PsA 
remained constant with time following the diagnosis of psoriasis (32). 
ii. Genetic factors  
There are genetic susceptibility factors common to both psoriasis and PsA. However some 
known genetic factors such as presence of the HLA-Cw6 allele are strongly associated with 
psoriasis and more so in younger patients than in PsA itself. Therefore it is likely that there 
are additional genetic factors that are associated with susceptibility to PsA other than those 
for skin psoriasis alone.  Three such loci appear to be IL-13, HLA-B27 and PTPN22 (33, 34). 
The presence of HLA-B27 is associated with a shorter interval between the onset of psoriasis 
and the onset of PsA (35). Furthermore, different combinations of HLA-B and C alleles and 
haplotypes may be associated with particular phenotypes and disease severity (36). 
 
iii. Other Biomarkers 
Osteoclast precursors are upregulated in PsA and can be identified by cellular markers such 
dendritic cell specific membrane protein (DC-STAMP). There is data to suggest that patients 
with psoriasis who develop arthritis show increased DC-STAMP expression on peripheral 
blood mononuclear cells (37). Measurement requires freshly isolated cells and access to 
flow cytometry and so is not at present a feasible strategy for screening. Other soluble 
biomarkers that can be more readily measured are of interest and bone turnover markers 
have been the subject of a recent systematic review (38). Markers that appear to 
differentiate psoriatic arthritis from psoriasis include matrix metalloproteinase-3 (MMP-3), 
dickkopf 1 (DKK-1), macrophage colony stimulating factor (M-CSF), a ratio of type II collagen 
synthesis to degradation (CPII:C2C) and possibly osteoprotegerin. Increased levels of highly 
sensitive CRP (hsCRP) may also be discriminatory (39). These markers need further study in 
a prospective cohort of patients with psoriasis to test their predictive value. 
 
Conclusions 
 
The long term outcome of psoriatic arthritis in those patients referred to a rheumatology 
service carries a high disease burden. Less is known of the outcome in patients who do not 
seek medical attention or who remain undiagnosed.  The estimated mean health cost is high 
especially in those with severe loss of physical function (40). There are high levels of 
unemployment and loss of productivity that may be more readily reversible with early 
intervention (41).  With the development of treat to target regimes using more effective 
therapies the case for early intervention is even stronger. Individuals with psoriasis who 
would appear to be at most risk are those who are obese, have nail disease and carry the 
HLA-B27 allele. However more knowledge is needed to create robust bioprofiles that can be 
applied to clinical phenotypes that stratify patients into appropriate treatment pathways 
and help implement effective screening strategies.  
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